Vaccinex Posts Two Complete Responses In Pepinemab Combo Trial In Head & Neck CancerBenzinga • 01/26/22
Vaccinex Reports Two Complete Responses in First Three Patients Enrolled in the Phase 1b/2 KEYNOTE-B84 Study of Pepinemab in Combination with KEYTRUDA (pembrolizumab) in Patients with Recurrent or Metastatic Head and Neck CancerGlobeNewsWire • 01/26/22
Vaccinex Reports Phase Ib KEYNOTE B84 Combination Study of Keytruda® and Pepinemab in Patients with Advanced, Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) Passes Planned Interim Safety AnalysisGlobeNewsWire • 01/04/22
Vaccinex, Inc. to Present at the Society for Immunotherapy of Cancer's (SITC) 36th Annual MeetingGlobeNewsWire • 11/10/21
Vaccinex, Inc. to Present at the Clinical Trials on Alzheimer's Disease (CTAD) MeetingGlobeNewsWire • 11/09/21
Vaccinex Reports Third Quarter 2021 Financial Results and Provides Corporate UpdateGlobeNewsWire • 11/08/21
Vaccinex, Inc. to Present at the 12th Annual Jefferies London Healthcare ConferenceGlobeNewsWire • 11/04/21
Vaccinex to Present at the Virtual Huntington's Study Group Meeting on November 4-6, 2021GlobeNewsWire • 11/01/21
Vaccinex to Present at the Oppenheimer & Co. Inc. Fall Healthcare Life Sciences and MedTech SummitGlobeNewsWire • 09/17/21
Vaccinex Reports Second Quarter 2021 Financial Results and Provides Corporate UpdateGlobeNewsWire • 08/16/21
Vaccinex to Chair Panel Q&A Session and Present Poster at the XV European Meeting on Glial Cells in Health and DiseaseGlobeNewsWire • 06/30/21
Vaccinex Announces Activation of Clinical Sites to Enroll Patients in Studies of Pepinemab as Single Agent in Alzheimer's Disease and in Combination with KEYTRUDA® in Advanced, Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)GlobeNewsWire • 06/08/21
Vaccinex Reports First Quarter 2021 Financial Results and Provides Corporate UpdateGlobeNewsWire • 05/17/21
Vaccinex Announces Publication of Results from CLASSICAL-Lung Phase 1b/2 Clinical Trial in Non-Small Cell Lung Cancer in the Peer-Reviewed Journal Clinical Cancer ResearchGlobeNewsWire • 04/21/21
Vaccinex Reports Fourth Quarter 2020 Financial Results and Provides Corporate UpdateGlobeNewsWire • 03/16/21
Vaccinex stock soars 223% on partnership deals using its antibody discovery platform (VCNX)Business Insider • 02/19/21
Vaccinex's stock soars toward record gain on record volume after deals with 'prominent' drug makersMarket Watch • 02/19/21
VCNX Stock: 11 Things to Know About Vaccinex and the Deals That Have Shares SoaringInvestorPlace • 02/19/21